干细胞疗法能否像多肽一样获 FDA 青睐?支持者认为 RFK Jr. 或促成变革
STAT+: Are stem cells the next peptides? These advocates think RFK Jr. could make it happen
干细胞企业家 Chuck Meeker 认为 FDA 可能对干细胞疗法采取类似多肽的监管策略。尽管 FDA 未确认是否即将召开圆桌会议,但该行业代表预计年底前将举行一系列 FDA 圆桌会议,旨在推动未获批的干细胞疗法从灰色市场进入合法渠道。
![]()
Oct. 5, 2026
Manto attended a conference filled with peptide proponents and spoke to regenerative medicine experts and former regulators for this article.
WASHINGTON — Stem cell entrepreneur Chuck Meeker is bullish about his industry’s prospects with the Food and Drug Administration nowadays.
“If I were a betting man, I would say before the end of the year we have a series of FDA roundtables happening,” Meeker told STAT at PepMed 2026, a conference for regenerative health businesses held by the American Academy of Peptide Medicine. (The FDA declined to say whether such events were imminent.)
That stem cells made an appearance at a conference centered on peptides isn’t a coincidence. Peptides and stem cells are two peas in the pod of regenerative medicine, which focuses on therapies that claim to trigger the body’s natural healing mechanisms. But while compounded peptides are having a bit of a moment with the FDA, commercially available, unapproved stem cell therapies have remained a black sheep for the agency.
Meeker and others at PepMed told STAT they believe that’s about to change. The stem cell industry sees the FDA’s tentative embrace of peptides as its chance to get a foot in the door — and bring stem cells from the grey market to millions of Americans.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源:STAT 主站 · statnews.com